For the Inventor, By the Inventor

Enter assignee name

Gyeonggi-do, South Korea

Olix Pharmaceuticals, Inc.

USPTO Granted Patents = 16

CIPO Patents = 1

EPO Patents = 6

Trademarks = 1

Forward Citations = 41

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Sun Woo Hong (13 out of 13 patents)

Dong Ki Lee (8 out of 17 patents)

Isu Hong (4 out of 4 patents)

4. Ji Hyun Kim (4 out of 131 patents)

5. Hanna Lee (3 out of 12 patents)

6. Ji Eom (3 out of 3 patents)

7. Dayeon Yu (3 out of 3 patents)

8. Jihye Hwang (3 out of 4 patents)

9. Tae Yeon Lee (3 out of 3 patents)

10. Dong-Ki Lee (2 out of 29 patents)

11. Yu Ran Na (2 out of 2 patents)

12. Young-Dong Kim (2 out of 2 patents)

13. Sae-Lo-Oom Lee (2 out of 2 patents)

14. Yang Hee Kim (1 out of 22 patents)

15. Da Seul Son (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 12686867 - RNAi AGENT TARGETING MYD88 AND USE THEREOF (2026-07-21),

2. 11591600 - Long double-stranded RNA for RNA interference (2023-02-28),

3. 11118184 - Asymmetric siRNA for inhibiting expression of male pattern hair loss target gene (2021-09-14),

4. 11040057 - Pharmaceutical compositions and methods for potentiating gene silencing (2021-06-22),

5. 10947541 - Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (2021-03-16),

6. 10883105 - RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor (2021-01-05),

7. 10829761 - Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (2020-11-10),

8. 10829760 - Nucleic acid molecules inducing RNA interference, and uses thereof (2020-11-10),

9. 10590423 - Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 (2020-03-17),

10. 10519449 - Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB (2019-12-31),

11. 10512600 - RNA complexes that inhibit melanin production (2019-12-24),

12. 10358648 - Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 (2019-07-23),

13. 10301628 - Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor (2019-05-28),

14. 10125362 - RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor (2018-11-13),

15. 10064801 - RNA complexes that inhibit melanin production (2018-09-04),

Company Overview

Olix Pharmaceuticals, Inc. is a biopharmaceutical company based in Gyeonggi-do, South Korea, specializing in the development of innovative RNA therapeutics. The company focuses on leveraging its proprietary platform to create treatments for various diseases, including genetic disorders and cancers. With a commitment to advancing the field of RNA-based medicine, Olix aims to address unmet medical needs through its cutting-edge research and development efforts, positioning itself as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#53 in Gyeonggi-do

#745 in South Korea

#37,831 in the World

Gyeonggi-do, South Korea

Olix Pharmaceuticals, Inc.

Forward Citations = 41

16 inventors:

Sun Woo Hong (13 out of 13 patents)

Dong Ki Lee (8 out of 17 patents)

Isu Hong (4 out of 4 patents)

4. Ji Hyun Kim (4 out of 131 patents)

5. Hanna Lee (3 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Olix Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/olix-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…